Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS
Written by
American Journal Managed Care
Published
0
comments
0
min
In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses while reducing financial and toxicity burdens, with decisions guided by residual disease testing and shared decision-making, explained Jonathan Thompson, MD, MS.